AMERICAN SOCIETY FOR RADIATION ONCOLOGY
JM
The past 12 months
Clients
1
past 12 months
Filings
1
past 12 months
Agencies contacted
Centers For Medicare and Medicaid Services (CMS)Executive Office of the President (EOP)Food & Drug Administration (FDA)HOUSE OF REPRESENTATIVESHealth & Human Services, Dept of (HHS)Natl Institutes of Health (NIH)Nuclear Regulatory Commission (NRC)Office of Management & Budget (OMB)SENATE
Specific issues
FY2027 LHHS Appropriations bill-funding for NIH/NCI Access to radioactive isotopes Support for NRC Commissioner nominee to have medical background Radiation Oncology reimbursement Policy initiatives designed to increase transparency in the prior authorization process Efforts to educate legislators about unintended consequences associated with rate setting for health care services Preserve current training and experience requirements for radiopharmaceuticals Support current NRC medical event reporting regulations and patient safety protocols without additional requirements for extravasations
Oppose CMS's "efficiency adjustment" Support for structural changes that lead to delivering high quality care for patients while increasing efficiencies and promoting Medicare sustainability; oppose radiation oncology benefit managers Support for reforming the way Medicare pays for radiation oncology services by tying payments to quality and value Support for protecting access to care for Medicare patients Oppose physician fee schedule cuts due to clinical labor price updates Support for H.R. 2120 and S. 1031, a bill to modernize radiation oncology reimbursement - The Radiation Oncology Case Rate Value Based Program Act of 2025 Support for H.R. 879, to fix Medicare Physician Fee Schedule's physician payment reimbursement cuts Support H.R.3514, S.1816, the Improving Seniors' Timely Access to Care Act Support for H.R. 6160, Strengthening Medicare for Patients and Providers Act
Support legislation to increase the budget for the National Institutes of Health, National Cancer Institute and the Centers for Disease Control and Prevention for FY 2026 and FY2027 Support for increased funding for radiation therapy cooperative groups within the National Cancer Institute Support for the National Institutes of Health to recognize radiation oncology as an individual specialty in reporting systems to create more transparency of federal appropriations Support for ARPA-H to support innovative cancer treatments Support for initiatives to increase diversity in clinical trials Support for DOD lung cancer research program funding Support for report language encouraging NIH to support research into functional radiation medicine
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Nuclear Regulatory Commission (NRC)
Clients
Sources
This profile is built from the public record: filings in the U.S. Senate Lobbying Disclosure Act system. lda.senate.gov ↗
Recent filings1
lda.gov →